Gambogic acid induces apoptosis in diffuse large B-cell lymphoma cells via inducing proteasome inhibition

Xianping Shi; Xiaoying Lan; Xin Chen; Chong Zhao; Xiaofen Li; Shouting Liu; Hongbiao Huang; Ningning Liu; Dan Zang; Yuning Liao; Peiquan Zhang; Xuejun Wang; Jinbao Liu

doi:10.1038/srep09694

Gambogic acid induces apoptosis in diffuse large B-cell lymphoma cells via inducing proteasome inhibition

Xianping Shi, Xiaoying Lan, Xin Chen, Chong Zhao, Xiaofen Li, Shouting Liu, Hongbiao Huang, Ningning Liu, Dan Zang, Yuning Liao, Peiquan Zhang, Xuejun Wang, Jinbao Liu

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Abstract

Resistance to chemotherapy is a great challenge to improving the survival of patients with diffuse large B-cell lymphoma (DLBCL), especially those with activated B-cell-like DLBCL (ABC-DLBCL). Therefore it is urgent to search for novel agents for the treatment of DLBCL. Gambogic acid (GA), a small molecule derived from Chinese herb gamboges, has been approved for Phase II clinical trial for cancer therapy by Chinese FDA. In the present study, we investigated the effect of GA on cell survival and apoptosis in DLBCL cells including both GCB- and ABC-DLBCL cells. We found that GA induced growth inhibition and apoptosis of both GCB- and ABC-DLBCL cells in vitro and in vivo, which is associated with proteasome malfunction. These findings provide significant pre-clinical evidence for potential usage of GA in DLBCL therapy particularly in ABC-DLBCL treatment.

Original language	English (US)
Article number	9694
Journal	Scientific reports
Volume	5
DOIs	https://doi.org/10.1038/srep09694
State	Published - Apr 13 2015
Externally published	Yes

ASJC Scopus subject areas

General

Access to Document

10.1038/srep09694

Cite this

@article{5d098c7158dd4696a9b759a3847395e9,

title = "Gambogic acid induces apoptosis in diffuse large B-cell lymphoma cells via inducing proteasome inhibition",

abstract = "Resistance to chemotherapy is a great challenge to improving the survival of patients with diffuse large B-cell lymphoma (DLBCL), especially those with activated B-cell-like DLBCL (ABC-DLBCL). Therefore it is urgent to search for novel agents for the treatment of DLBCL. Gambogic acid (GA), a small molecule derived from Chinese herb gamboges, has been approved for Phase II clinical trial for cancer therapy by Chinese FDA. In the present study, we investigated the effect of GA on cell survival and apoptosis in DLBCL cells including both GCB- and ABC-DLBCL cells. We found that GA induced growth inhibition and apoptosis of both GCB- and ABC-DLBCL cells in vitro and in vivo, which is associated with proteasome malfunction. These findings provide significant pre-clinical evidence for potential usage of GA in DLBCL therapy particularly in ABC-DLBCL treatment.",

author = "Xianping Shi and Xiaoying Lan and Xin Chen and Chong Zhao and Xiaofen Li and Shouting Liu and Hongbiao Huang and Ningning Liu and Dan Zang and Yuning Liao and Peiquan Zhang and Xuejun Wang and Jinbao Liu",

year = "2015",

month = apr,

day = "13",

doi = "10.1038/srep09694",

language = "English (US)",

volume = "5",

journal = "Scientific reports",

issn = "2045-2322",

publisher = "Nature Research",

}

TY - JOUR

T1 - Gambogic acid induces apoptosis in diffuse large B-cell lymphoma cells via inducing proteasome inhibition

AU - Shi, Xianping

AU - Lan, Xiaoying

AU - Chen, Xin

AU - Zhao, Chong

AU - Li, Xiaofen

AU - Liu, Shouting

AU - Huang, Hongbiao

AU - Liu, Ningning

AU - Zang, Dan

AU - Liao, Yuning

AU - Zhang, Peiquan

AU - Wang, Xuejun

AU - Liu, Jinbao

PY - 2015/4/13

Y1 - 2015/4/13

N2 - Resistance to chemotherapy is a great challenge to improving the survival of patients with diffuse large B-cell lymphoma (DLBCL), especially those with activated B-cell-like DLBCL (ABC-DLBCL). Therefore it is urgent to search for novel agents for the treatment of DLBCL. Gambogic acid (GA), a small molecule derived from Chinese herb gamboges, has been approved for Phase II clinical trial for cancer therapy by Chinese FDA. In the present study, we investigated the effect of GA on cell survival and apoptosis in DLBCL cells including both GCB- and ABC-DLBCL cells. We found that GA induced growth inhibition and apoptosis of both GCB- and ABC-DLBCL cells in vitro and in vivo, which is associated with proteasome malfunction. These findings provide significant pre-clinical evidence for potential usage of GA in DLBCL therapy particularly in ABC-DLBCL treatment.

AB - Resistance to chemotherapy is a great challenge to improving the survival of patients with diffuse large B-cell lymphoma (DLBCL), especially those with activated B-cell-like DLBCL (ABC-DLBCL). Therefore it is urgent to search for novel agents for the treatment of DLBCL. Gambogic acid (GA), a small molecule derived from Chinese herb gamboges, has been approved for Phase II clinical trial for cancer therapy by Chinese FDA. In the present study, we investigated the effect of GA on cell survival and apoptosis in DLBCL cells including both GCB- and ABC-DLBCL cells. We found that GA induced growth inhibition and apoptosis of both GCB- and ABC-DLBCL cells in vitro and in vivo, which is associated with proteasome malfunction. These findings provide significant pre-clinical evidence for potential usage of GA in DLBCL therapy particularly in ABC-DLBCL treatment.

UR - http://www.scopus.com/inward/record.url?scp=84927918833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927918833&partnerID=8YFLogxK

U2 - 10.1038/srep09694

DO - 10.1038/srep09694

M3 - Article

C2 - 25853502

AN - SCOPUS:84927918833

SN - 2045-2322

VL - 5

JO - Scientific reports

JF - Scientific reports

M1 - 9694

ER -

Gambogic acid induces apoptosis in diffuse large B-cell lymphoma cells via inducing proteasome inhibition

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this